4 Stocks Pulling The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 52 points (0.3%) at 15,523 as of Thursday, Aug. 8, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,945 issues advancing vs. 956 declining with 122 unchanged.

The Health Care sector currently sits down 0.7% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the sector include Amgen ( AMGN), down 1.3%, and Pfizer ( PFE), down 0.6%. Top gainers within the sector include DexCom ( DXCM), up 23.7%, ResMed ( RMD), up 3.4%, Valeant Pharmaceuticals International ( VRX), up 2.7%, HCA Holdings ( HCA), up 1.7% and Boston Scientific ( BSX), up 1.6%.

TheStreet would like to highlight 4 stocks pushing the sector lower today:

4. BioScrip ( BIOS) is one of the companies pushing the Health Care sector lower today. As of noon trading, BioScrip is down $2.48 (-14.9%) to $14.15 on heavy volume. Thus far, 1.8 million shares of BioScrip exchanged hands as compared to its average daily volume of 582,200 shares. The stock has ranged in price between $14.05-$15.13 after having opened the day at $15.00 as compared to the previous trading day's close of $16.63.

BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. BioScrip has a market cap of $1.1 billion and is part of the drugs industry. Shares are up 51.0% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates BioScrip as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and poor profit margins. Get the full BioScrip Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $1.30 (-1.1%) to $113.35 on light volume. Thus far, 305,703 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $112.74-$115.25 after having opened the day at $114.93 as compared to the previous trading day's close of $114.65.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $22.4 billion and is part of the drugs industry. Shares are up 22.0% year to date as of the close of trading on Wednesday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Actavis ( ACT) is down $1.35 (-1.0%) to $134.08 on light volume. Thus far, 311,268 shares of Actavis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $133.70-$136.32 after having opened the day at $135.72 as compared to the previous trading day's close of $135.43.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $18.1 billion and is part of the drugs industry. Shares are up 57.5% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Actavis a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is down $0.68 (-0.7%) to $92.98 on average volume. Thus far, 5.7 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.9 million shares. The stock has ranged in price between $92.71-$94.37 after having opened the day at $94.27 as compared to the previous trading day's close of $93.66.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $264.4 billion and is part of the drugs industry. Shares are up 33.6% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Johnson & Johnson Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists